#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-4	Weak	_
1-2	5-17	dorsolateral	_
1-3	18-28	prefrontal	_
1-4	29-37	response	_
1-5	38-40	to	_
1-6	41-47	social	_
1-7	48-57	criticism	_
1-8	58-66	predicts	_
1-9	67-75	worsened	_
1-10	76-80	mood	_
1-11	81-84	and	_
1-12	85-93	symptoms	_
1-13	94-103	following	_
1-14	104-110	social	_
1-15	111-119	conflict	_
1-16	120-122	in	_
1-17	123-129	people	_
1-18	130-132	at	_
1-19	133-141	familial	_
1-20	142-146	risk	_
1-21	147-150	for	_
1-22	151-164	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	165-178	Understanding	_
1-24	179-182	the	_
1-25	183-191	specific	_
1-26	192-202	mechanisms	_
1-27	203-207	that	_
1-28	208-215	explain	_
1-29	216-219	why	_
1-30	220-226	people	_
1-31	227-230	who	_
1-32	231-235	have	_
1-33	236-245	relatives	_
1-34	246-250	with	_
1-35	251-264	schizophrenia	_
1-36	265-266	(	_
1-37	267-271	i.e.	_
1-38	272-273	,	_
1-39	274-280	people	_
1-40	281-283	at	_
1-41	284-292	familial	_
1-42	293-297	high	_
1-43	298-302	risk	_
1-44	303-304	;	_
1-45	305-308	FHR	_
1-46	309-310	)	_
1-47	311-314	are	_
1-48	315-319	more	_
1-49	320-326	likely	_
1-50	327-329	to	_
1-51	330-337	develop	_
1-52	338-341	the	_
1-53	342-350	disorder	_
1-54	351-353	is	_
1-55	354-361	crucial	_
1-56	362-365	for	_
1-57	366-376	prevention	_
1-58	377-378	.	_

2-1	379-381	We	_
2-2	382-394	investigated	_
2-3	395-396	a	_
2-4	397-413	diathesis-stress	_
2-5	414-419	model	_
2-6	420-422	of	_
2-7	423-431	familial	_
2-8	432-436	risk	_
2-9	437-439	by	_
2-10	440-447	testing	_
2-11	448-455	whether	_
2-12	456-459	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
2-13	460-471	individuals	_
2-14	472-485	under-recruit	_
2-15	486-491	brain	_
2-16	492-499	regions	_
2-17	500-507	central	_
2-18	508-510	to	_
2-19	511-518	emotion	_
2-20	519-529	regulation	_
2-21	530-534	when	_
2-22	535-542	exposed	_
2-23	543-545	to	_
2-24	546-552	social	_
2-25	553-561	conflict	_
2-26	562-563	,	_
2-27	564-573	resulting	_
2-28	574-576	in	_
2-29	577-582	worse	_
2-30	583-587	mood	_
2-31	588-591	and	_
2-32	592-600	symptoms	_
2-33	601-610	following	_
2-34	611-619	conflict	_
2-35	620-621	.	_

3-1	622-625	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-2	626-629	and	_
3-3	630-637	non-FHR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
3-4	638-650	participants	_
3-5	651-659	listened	_
3-6	660-662	to	_
3-7	663-671	critical	_
3-8	672-673	,	_
3-9	674-681	neutral	_
3-10	682-683	,	_
3-11	684-687	and	_
3-12	688-696	praising	_
3-13	697-705	comments	_
3-14	706-708	in	_
3-15	709-711	an	_
3-16	712-716	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-17	717-724	scanner	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-18	725-731	before	_
3-19	732-742	completing	_
3-20	743-744	4	_
3-21	745-750	weeks	_
3-22	751-753	of	_
3-23	754-765	daily-diary	_
3-24	766-773	records	_
3-25	774-775	.	_

4-1	776-784	Compared	_
4-2	785-787	to	_
4-3	788-795	non-FHR	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-4	796-807	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-5	808-809	,	_
4-6	810-813	FHR	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-7	814-825	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-8	826-841	under-recruited	_
4-9	842-845	the	_
4-10	846-855	bilateral	_
4-11	856-868	dorsolateral	_
4-12	869-879	prefrontal	_
4-13	880-886	cortex	_
4-14	887-888	(	_
4-15	889-894	DLPFC	_
4-16	895-896	)	_
4-17	897-899	—a	_
4-18	900-906	region	_
4-19	907-915	strongly	_
4-20	916-926	implicated	_
4-21	927-929	in	_
4-22	930-939	cognitive	_
4-23	940-947	emotion	_
4-24	948-968	regulation—following	_
4-25	969-978	criticism	_
4-26	979-980	.	_

5-1	981-992	Furthermore	_
5-2	993-994	,	_
5-3	995-1001	within	_
5-4	1002-1005	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-5	1006-1018	participants	_
5-6	1019-1020	,	_
5-7	1021-1025	weak	_
5-8	1026-1031	DLPFC	_
5-9	1032-1040	response	_
5-10	1041-1043	to	_
5-11	1044-1053	criticism	_
5-12	1054-1056	in	_
5-13	1057-1060	the	_
5-14	1061-1071	laboratory	_
5-15	1072-1076	task	_
5-16	1077-1080	was	_
5-17	1081-1091	associated	_
5-18	1092-1096	with	_
5-19	1097-1105	elevated	_
5-20	1106-1114	negative	_
5-21	1115-1119	mood	_
5-22	1120-1123	and	_
5-23	1124-1132	positive	_
5-24	1133-1141	symptoms	_
5-25	1142-1144	on	_
5-26	1145-1149	days	_
5-27	1150-1154	with	_
5-28	1155-1166	distressing	_
5-29	1167-1173	social	_
5-30	1174-1183	conflicts	_
5-31	1184-1186	in	_
5-32	1187-1198	daily-diary	_
5-33	1199-1210	assessments	_
5-34	1211-1212	.	_

6-1	1213-1220	Results	_
6-2	1221-1227	extend	_
6-3	1228-1244	diathesis-stress	_
6-4	1245-1251	models	_
6-5	1252-1254	of	_
6-6	1255-1268	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-7	1269-1271	by	_
6-8	1272-1282	clarifying	_
6-9	1283-1289	neural	_
6-10	1290-1293	and	_
6-11	1294-1307	environmental	_
6-12	1308-1316	pathways	_
6-13	1317-1319	to	_
6-14	1320-1333	dysregulation	_
6-15	1334-1336	in	_
6-16	1337-1340	FHR	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-17	1341-1352	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-18	1353-1354	.	_

7-1	1355-1365	Highlights	_
7-2	1366-1372	People	_
7-3	1373-1375	at	_
7-4	1376-1384	familial	_
7-5	1385-1389	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
7-6	1390-1393	for	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
7-7	1394-1407	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-8	1408-1414	showed	_
7-9	1415-1422	reduced	_
7-10	1423-1428	DLPFC	_
7-11	1429-1437	activity	_
7-12	1438-1447	following	_
7-13	1448-1457	criticism	_
7-14	1458-1459	.	_

8-1	1460-1467	Reduced	_
8-2	1468-1473	DLPFC	_
8-3	1474-1482	activity	_
8-4	1483-1492	following	_
8-5	1493-1502	criticism	_
8-6	1503-1512	predicted	_
8-7	1513-1518	worse	_
8-8	1519-1528	responses	_
8-9	1529-1531	to	_
8-10	1532-1538	actual	_
8-11	1539-1545	social	_
8-12	1546-1555	conflicts	_
8-13	1556-1557	.	_

9-1	1558-1562	Weak	_
9-2	1563-1569	neural	_
9-3	1570-1580	regulation	_
9-4	1581-1583	of	_
9-5	1584-1591	emotion	_
9-6	1592-1600	combined	_
9-7	1601-1605	with	_
9-8	1606-1612	social	_
9-9	1613-1621	conflict	_
9-10	1622-1625	may	_
9-11	1626-1633	promote	_
9-12	1634-1641	symptom	_
9-13	1642-1653	development	_
9-14	1654-1656	in	_
9-15	1657-1664	at-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
9-16	1665-1676	individuals	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
9-17	1677-1678	.	_

10-1	1679-1687	Material	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1688-1691	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1692-1699	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1700-1712	Participants	_
10-5	1713-1723	Twenty-one	_
10-6	1724-1727	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-7	1728-1731	and	_
10-8	1732-1734	20	_
10-9	1735-1742	non-FHR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
10-10	1743-1754	individuals	_
10-11	1755-1763	enrolled	_
10-12	1764-1766	in	_
10-13	1767-1770	the	_
10-14	1771-1776	study	_
10-15	1777-1780	and	_
10-16	1781-1790	completed	_
10-17	1791-1794	the	_
10-18	1795-1799	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
10-19	1800-1804	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
10-20	1805-1806	.	_

11-1	1807-1809	We	_
11-2	1810-1818	excluded	_
11-3	1819-1820	1	_
11-4	1821-1828	non-FHR	_
11-5	1829-1840	participant	_
11-6	1841-1844	due	_
11-7	1845-1847	to	_
11-8	1848-1857	excessive	_
11-9	1858-1864	motion	_
11-10	1865-1866	.	_

12-1	1867-1870	All	_
12-2	1871-1878	non-FHR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
12-3	1879-1891	participants	_
12-4	1892-1895	and	_
12-5	1896-1898	17	_
12-6	1899-1902	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-7	1903-1915	participants	_
12-8	1916-1920	then	_
12-9	1921-1930	completed	_
12-10	1931-1932	4	_
12-11	1933-1938	weeks	_
12-12	1939-1941	of	_
12-13	1942-1953	daily-diary	_
12-14	1954-1968	questionnaires	_
12-15	1969-1970	.	_

13-1	1971-1983	Consequently	_
13-2	1984-1985	,	_
13-3	1986-1989	for	_
13-4	1990-1994	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
13-5	1995-2003	analyses	_
13-6	2004-2005	,	_
13-7	2006-2010	NFHR	_
13-8	2011-2012	=	_
13-9	2013-2015	21	_
13-10	2016-2019	and	_
13-11	2020-2028	Nnon-FHR	_
13-12	2029-2030	=	_
13-13	2031-2033	19	_
13-14	2034-2035	.	_

14-1	2036-2039	For	_
14-2	2040-2051	daily-diary	_
14-3	2052-2060	analyses	_
14-4	2061-2062	,	_
14-5	2063-2067	NFHR	_
14-6	2068-2069	=	_
14-7	2070-2072	17	_
14-8	2073-2076	and	_
14-9	2077-2085	Nnon-FHR	_
14-10	2086-2087	=	_
14-11	2088-2090	19	_
14-12	2091-2092	(	_
14-13	2093-2096	see	_
14-14	2097-2102	Table	_
14-15	2103-2104	1	_
14-16	2105-2108	for	_
14-17	2109-2120	participant	_
14-18	2121-2128	details	_
14-19	2129-2130	)	_
14-20	2131-2132	.	_

15-1	2133-2136	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-2	2137-2149	participants	_
15-3	2150-2154	were	_
15-4	2155-2163	required	_
15-5	2164-2166	to	_
15-6	2167-2169	be	_
15-7	2170-2177	between	_
15-8	2178-2180	15	_
15-9	2181-2184	and	_
15-10	2185-2187	32	_
15-11	2188-2193	years	_
15-12	2194-2196	of	_
15-13	2197-2200	age	_
15-14	2201-2204	and	_
15-15	2205-2209	have	_
15-16	2210-2211	a	_
15-17	2212-2220	relative	_
15-18	2221-2223	or	_
15-19	2224-2233	relatives	_
15-20	2234-2243	diagnosed	_
15-21	2244-2248	with	_
15-22	2249-2258	psychotic	_
15-23	2259-2268	disorders	_
15-24	2269-2270	.	_

16-1	2271-2274	All	_
16-2	2275-2278	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-3	2279-2291	participants	_
16-4	2292-2295	had	_
16-5	2296-2298	at	_
16-6	2299-2304	least	_
16-7	2305-2308	one	_
16-8	2309-2321	first-degree	_
16-9	2322-2330	relative	_
16-10	2331-2335	with	_
16-11	2336-2349	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-12	2350-2352	or	_
16-13	2353-2368	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
16-14	2369-2377	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
16-15	2378-2379	,	_
16-16	2380-2383	and	_
16-17	2384-2387	all	_
16-18	2388-2391	but	_
16-19	2392-2393	2	_
16-20	2394-2397	had	_
16-21	2398-2399	a	_
16-22	2400-2406	second	_
16-23	2407-2419	first-degree	_
16-24	2420-2428	relative	_
16-25	2429-2433	with	_
16-26	2434-2437	one	_
16-27	2438-2440	of	_
16-28	2441-2446	these	_
16-29	2447-2456	disorders	_
16-30	2457-2458	.	_

17-1	2459-2466	Non-FHR	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
17-2	2467-2479	participants	_
17-3	2480-2483	had	_
17-4	2484-2486	no	_
17-5	2487-2493	family	_
17-6	2494-2501	history	_
17-7	2502-2504	of	_
17-8	2505-2514	psychotic	_
17-9	2515-2524	disorders	_
17-10	2525-2526	,	_
17-11	2527-2538	psychiatric	_
17-12	2539-2554	hospitalization	_
17-13	2555-2556	,	_
17-14	2557-2559	or	_
17-15	2560-2567	suicide	_
17-16	2568-2569	.	_

18-1	2570-2579	Exclusion	_
18-2	2580-2588	criteria	_
18-3	2589-2592	for	_
18-4	2593-2597	both	_
18-5	2598-2601	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-6	2602-2605	and	_
18-7	2606-2613	non-FHR	_
18-8	2614-2626	participants	_
18-9	2627-2635	included	_
18-10	2636-2648	past/current	_
18-11	2649-2658	treatment	_
18-12	2659-2663	with	_
18-13	2664-2679	anti-psychotics	_
18-14	2680-2682	or	_
18-15	2683-2687	mood	_
18-16	2688-2699	stabilizers	_
18-17	2700-2701	,	_
18-18	2702-2704	IQ	_
18-19	2705-2706	<	_
18-20	2707-2709	70	_
18-21	2710-2711	,	_
18-22	2712-2717	being	_
18-23	2718-2719	a	_
18-24	2720-2730	non-native	_
18-25	2731-2738	English	_
18-26	2739-2746	speaker	_
18-27	2747-2748	,	_
18-28	2749-2753	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
18-29	2754-2770	contraindication	_
18-30	2771-2772	,	_
18-31	2773-2776	and	_
18-32	2777-2781	past	_
18-33	2782-2784	or	_
18-34	2785-2792	current	_
18-35	2793-2799	DSM-IV	_
18-36	2800-2806	Axis-I	_
18-37	2807-2816	psychotic	_
18-38	2817-2826	disorders	_
18-39	2827-2828	(	_
18-40	2829-2833	i.e.	_
18-41	2834-2835	,	_
18-42	2836-2849	schizophrenia	_
18-43	2850-2851	,	_
18-44	2852-2867	schizoaffective	_
18-45	2868-2876	disorder	_
18-46	2877-2878	,	_
18-47	2879-2892	psychosis-NOS	_
18-48	2893-2894	,	_
18-49	2895-2912	substance-induced	_
18-50	2913-2922	psychosis	_
18-51	2923-2924	,	_
18-52	2925-2927	or	_
18-53	2928-2941	bipolar/major	_
18-54	2942-2952	depressive	_
18-55	2953-2961	disorder	_
18-56	2962-2966	with	_
18-57	2967-2976	psychotic	_
18-58	2977-2985	features	_
18-59	2986-2987	)	_
18-60	2988-2989	.	_

19-1	2990-2997	Neither	_
19-2	2998-3001	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-3	3002-3005	nor	_
19-4	3006-3013	non-FHR	_
19-5	3014-3026	participants	_
19-6	3027-3031	were	_
19-7	3032-3040	excluded	_
19-8	3041-3044	for	_
19-9	3045-3050	other	_
19-10	3051-3057	Axis-I	_
19-11	3058-3067	disorders	_
19-12	3068-3069	.	_

20-1	3070-3074	This	_
20-2	3075-3085	maintained	_
20-3	3086-3089	the	_
20-4	3090-3108	representativeness	_
20-5	3109-3112	and	_
20-6	3113-3121	external	_
20-7	3122-3130	validity	_
20-8	3131-3133	of	_
20-9	3134-3137	our	_
20-10	3138-3144	sample	_
20-11	3145-3146	,	_
20-12	3147-3149	as	_
20-13	3150-3155	these	_
20-14	3156-3166	conditions	_
20-15	3167-3171	have	_
20-16	3172-3176	been	_
20-17	3177-3182	found	_
20-18	3183-3185	to	_
20-19	3186-3188	be	_
20-20	3189-3193	more	_
20-21	3194-3203	prevalent	_
20-22	3204-3206	in	_
20-23	3207-3210	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
20-24	3211-3222	individuals	_
20-25	3223-3227	than	_
20-26	3228-3231	the	_
20-27	3232-3239	general	_
20-28	3240-3250	population	_
20-29	3251-3252	.	_

21-1	3253-3255	We	_
21-2	3256-3260	used	_
21-3	3261-3264	the	_
21-4	3265-3275	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-5	3276-3285	Interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-6	3286-3289	for	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-7	3290-3297	Genetic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-8	3298-3305	Studies	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-9	3306-3307	(	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-10	3308-3312	DIGS	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-11	3313-3314	)	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-12	3315-3318	and	_
21-13	3319-3325	Family	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-14	3326-3335	Interview	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-15	3336-3339	for	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-16	3340-3347	Genetic	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-17	3348-3355	Studies	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-18	3356-3357	(	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-19	3358-3362	FIGS	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-20	3363-3364	)	http://maven.renci.org/NeuroBridge/neurobridge#DiagnosticInterviewforGeneticStudies
21-21	3365-3367	to	_
21-22	3368-3374	assess	_
21-23	3375-3383	personal	_
21-24	3384-3387	and	_
21-25	3388-3394	family	_
21-26	3395-3402	history	_
21-27	3403-3405	of	_
21-28	3406-3421	psychopathology	_
21-29	3422-3423	.	_

22-1	3424-3436	Participants	_
22-2	3437-3438	'	_
22-3	3439-3448	prodromal	_
22-4	3449-3458	psychotic	_
22-5	3459-3467	symptoms	_
22-6	3468-3472	were	_
22-7	3473-3481	measured	_
22-8	3482-3486	with	_
22-9	3487-3490	the	_
22-10	3491-3501	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-11	3502-3511	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-12	3512-3515	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-13	3516-3525	Prodromal	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-14	3526-3535	Syndromes	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-15	3536-3537	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-16	3538-3542	SIPS	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-17	3543-3544	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
22-18	3545-3546	.	_

23-1	3547-3549	IQ	_
23-2	3550-3553	was	_
23-3	3554-3562	assessed	_
23-4	3563-3567	with	_
23-5	3568-3571	the	_
23-6	3572-3580	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-7	3581-3592	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-8	3593-3598	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-9	3599-3601	of	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-10	3602-3614	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-11	3615-3616	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-12	3617-3621	WASI	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-13	3622-3623	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
23-14	3624-3625	.	_

24-1	3626-3629	The	_
24-2	3630-3634	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-3	3635-3645	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-4	3646-3655	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-5	3656-3657	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-6	3658-3664	BDI-II	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-7	3665-3666	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
24-8	3667-3670	and	_
24-9	3671-3682	State–Trait	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-10	3683-3690	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-11	3691-3700	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-12	3701-3702	(	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-13	3703-3707	STAI	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-14	3708-3709	)	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
24-15	3710-3718	assessed	_
24-16	3719-3729	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
24-17	3730-3733	and	_
24-18	3734-3741	anxiety	_
24-19	3742-3743	,	_
24-20	3744-3756	respectively	_
24-21	3757-3758	.	_

25-1	3759-3768	Expressed	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
25-2	3769-3776	emotion	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
25-3	3777-3781	task	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
25-4	3782-3791	Following	_
25-5	3792-3795	the	_
25-6	3796-3805	procedure	_
25-7	3806-3815	developed	_
25-8	3816-3818	by	_
25-9	3819-3825	Hooley	_
25-10	3826-3829	and	_
25-11	3830-3840	colleagues	_
25-12	3841-3842	,	_
25-13	3843-3855	participants	_
25-14	3856-3864	listened	_
25-15	3865-3867	to	_
25-16	3868-3873	audio	_
25-17	3874-3884	recordings	_
25-18	3885-3887	of	_
25-19	3888-3896	critical	_
25-20	3897-3898	,	_
25-21	3899-3906	neutral	_
25-22	3907-3908	,	_
25-23	3909-3912	and	_
25-24	3913-3921	praising	_
25-25	3922-3930	comments	_
25-26	3931-3937	spoken	_
25-27	3938-3940	in	_
25-28	3941-3944	the	_
25-29	3945-3950	third	_
25-30	3951-3957	person	_
25-31	3958-3967	presented	_
25-32	3968-3971	via	_
25-33	3972-3987	fMRI-compatible	_
25-34	3988-3998	headphones	_
25-35	3999-4000	.	_

26-1	4001-4013	Participants	_
26-2	4014-4022	listened	_
26-3	4023-4025	to	_
26-4	4026-4034	comments	_
26-5	4035-4038	for	_
26-6	4039-4041	20	_
26-7	4042-4043	s	_
26-8	4044-4045	,	_
26-9	4046-4052	freely	_
26-10	4053-4062	processed	_
26-11	4063-4066	and	_
26-12	4067-4076	reflected	_
26-13	4077-4079	on	_
26-14	4080-4088	comments	_
26-15	4089-4092	for	_
26-16	4093-4094	a	_
26-17	4095-4098	6-s	_
26-18	4099-4104	pause	_
26-19	4105-4111	period	_
26-20	4112-4113	,	_
26-21	4114-4117	and	_
26-22	4118-4122	then	_
26-23	4123-4126	had	_
26-24	4127-4128	4	_
26-25	4129-4130	s	_
26-26	4131-4133	to	_
26-27	4134-4138	rate	_
26-28	4139-4142	how	_
26-29	4143-4151	positive	_
26-30	4152-4154	or	_
26-31	4155-4163	negative	_
26-32	4164-4168	they	_
26-33	4169-4173	felt	_
26-34	4174-4179	after	_
26-35	4180-4184	each	_
26-36	4185-4192	comment	_
26-37	4193-4194	(	_
26-38	4195-4198	see	_
26-39	4199-4202	Fig	_
26-40	4203-4204	.	_

27-1	4205-4207	1a	_
27-2	4208-4211	for	_
27-3	4212-4216	task	_
27-4	4217-4224	details	_
27-5	4225-4226	)	_
27-6	4227-4228	.	_

28-1	4229-4241	Participants	_
28-2	4242-4250	imagined	_
28-3	4251-4255	that	_
28-4	4256-4260	each	_
28-5	4261-4268	comment	_
28-6	4269-4272	was	_
28-7	4273-4278	about	_
28-8	4279-4283	them	_
28-9	4284-4286	to	_
28-10	4287-4295	simulate	_
28-11	4296-4299	the	_
28-12	4300-4310	experience	_
28-13	4311-4313	of	_
28-14	4314-4319	being	_
28-15	4320-4330	criticized	_
28-16	4331-4332	,	_
28-17	4333-4342	neutrally	_
28-18	4343-4352	commented	_
28-19	4353-4355	on	_
28-20	4356-4357	,	_
28-21	4358-4361	and	_
28-22	4362-4369	praised	_
28-23	4370-4371	(	_
28-24	4372-4375	see	_
28-25	4376-4379	Fig	_
28-26	4380-4381	.	_

29-1	4382-4384	1b	_
29-2	4385-4388	for	_
29-3	4389-4396	example	_
29-4	4397-4405	comments	_
29-5	4406-4407	)	_
29-6	4408-4409	,	_
29-7	4410-4413	and	_
29-8	4414-4421	ratings	_
29-9	4422-4426	were	_
29-10	4427-4431	made	_
29-11	4432-4434	on	_
29-12	4435-4436	a	_
29-13	4437-4444	5-point	_
29-14	4445-4450	scale	_
29-15	4451-4452	(	_
29-16	4453-4454	1	_
29-17	4455-4456	=	_
29-18	4457-4461	very	_
29-19	4462-4470	positive	_
29-20	4471-4472	,	_
29-21	4473-4474	5	_
29-22	4475-4476	=	_
29-23	4477-4481	very	_
29-24	4482-4490	negative	_
29-25	4491-4492	)	_
29-26	4493-4494	.	_

30-1	4495-4498	The	_
30-2	4499-4503	task	_
30-3	4504-4512	included	_
30-4	4513-4514	4	_
30-5	4515-4521	trials	_
30-6	4522-4524	of	_
30-7	4525-4529	each	_
30-8	4530-4539	condition	_
30-9	4540-4541	,	_
30-10	4542-4548	evenly	_
30-11	4549-4554	split	_
30-12	4555-4559	into	_
30-13	4560-4563	two	_
30-14	4564-4568	runs	_
30-15	4569-4570	.	_

31-1	4571-4576	Trial	_
31-2	4577-4582	order	_
31-3	4583-4586	was	_
31-4	4587-4604	pseudo-randomized	_
31-5	4605-4606	.	_

32-1	4607-4609	We	_
32-2	4610-4618	analyzed	_
32-3	4619-4631	participants	_
32-4	4632-4633	'	_
32-5	4634-4641	average	_
32-6	4642-4646	mood	_
32-7	4647-4654	ratings	_
32-8	4655-4661	within	_
32-9	4662-4666	each	_
32-10	4667-4676	condition	_
32-11	4677-4682	using	_
32-12	4683-4684	a	_
32-13	4685-4686	2	_
32-14	4687-4692	Group	_
32-15	4693-4694	[	_
32-16	4695-4698	FHR	_
32-17	4699-4702	vs.	_
32-18	4703-4710	non-FHR	_
32-19	4711-4712	]	_
32-20	4713-4714	×	_
32-21	4715-4716	3	_
32-22	4717-4726	Condition	_
32-23	4727-4728	[	_
32-24	4729-4737	critical	_
32-25	4738-4741	vs.	_
32-26	4742-4749	neutral	_
32-27	4750-4753	vs.	_
32-28	4754-4762	praising	_
32-29	4763-4764	]	_
32-30	4765-4770	ANOVA	_
32-31	4771-4772	.	_

33-1	4773-4777	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-2	4778-4782	data	_
33-3	4783-4794	acquisition	_
33-4	4795-4798	and	_
33-5	4799-4809	processing	_
33-6	4810-4820	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
33-7	4821-4824	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
33-8	4825-4835	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-9	4836-4839	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-10	4840-4844	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
33-11	4845-4849	were	_
33-12	4850-4859	collected	_
33-13	4860-4862	on	_
33-14	4863-4864	a	_
33-15	4865-4872	3-Tesla	_
33-16	4873-4880	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#BoneMeasurement
33-17	4881-4888	scanner	_
33-18	4889-4894	using	_
33-19	4895-4896	a	_
33-20	4897-4907	12-channel	_
33-21	4908-4912	head	_
33-22	4913-4917	coil	_
33-23	4918-4919	.	_

34-1	4920-4931	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-2	4932-4942	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-3	4943-4949	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-4	4950-4954	were	_
34-5	4955-4963	acquired	_
34-6	4964-4969	using	_
34-7	4970-4980	multi-echo	_
34-8	4981-4987	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
34-9	4988-4997	sequences	_
34-10	4998-4999	(	_
34-11	5000-5003	176	_
34-12	5004-5012	sagittal	_
34-13	5013-5019	slices	_
34-14	5020-5021	,	_
34-15	5022-5023	1	_
34-16	5024-5026	mm	_
34-17	5027-5032	slice	_
34-18	5033-5042	thickness	_
34-19	5043-5044	)	_
34-20	5045-5046	.	_

35-1	5047-5058	Whole-brain	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
35-2	5059-5069	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
35-3	5070-5075	scans	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy
35-4	5076-5085	consisted	_
35-5	5086-5088	of	_
35-6	5089-5100	interleaved	_
35-7	5101-5112	echo-planar	_
35-8	5113-5119	images	_
35-9	5120-5128	acquired	_
35-10	5129-5131	in	_
35-11	5132-5135	the	_
35-12	5136-5149	oblique-axial	_
35-13	5150-5155	plane	_
35-14	5156-5157	(	_
35-15	5158-5160	40	_
35-16	5161-5167	slices	_
35-17	5168-5169	,	_
35-18	5170-5171	3	_
35-19	5172-5174	mm	_
35-20	5175-5185	isomorphic	_
35-21	5186-5192	voxels	_
35-22	5193-5194	,	_
35-23	5195-5197	TE	_
35-24	5198-5199	=	_
35-25	5200-5202	30	_
35-26	5203-5205	ms	_
35-27	5206-5207	,	_
35-28	5208-5210	TR	_
35-29	5211-5212	=	_
35-30	5213-5217	2560	_
35-31	5218-5220	ms	_
35-32	5221-5222	,	_
35-33	5223-5227	flip	_
35-34	5228-5233	angle	_
35-35	5234-5235	=	_
35-36	5236-5238	85	_
35-37	5239-5240	,	_
35-38	5241-5244	FOV	_
35-39	5245-5246	=	_
35-40	5247-5250	216	_
35-41	5251-5253	mm	_
35-42	5254-5255	×	_
35-43	5256-5259	216	_
35-44	5260-5262	mm	_
35-45	5263-5264	,	_
35-46	5265-5271	matrix	_
35-47	5272-5276	size	_
35-48	5277-5278	=	_
35-49	5279-5281	72	_
35-50	5282-5283	×	_
35-51	5284-5286	72	_
35-52	5287-5288	)	_
35-53	5289-5290	.	_

36-1	5291-5294	The	_
36-2	5295-5300	first	_
36-3	5301-5305	four	_
36-4	5306-5313	volumes	_
36-5	5314-5316	of	_
36-6	5317-5321	each	_
36-7	5322-5325	run	_
36-8	5326-5330	were	_
36-9	5331-5340	discarded	_
36-10	5341-5343	to	_
36-11	5344-5353	stabilize	_
36-12	5354-5360	signal	_
36-13	5361-5362	.	_

37-1	5363-5367	Data	_
37-2	5368-5372	were	_
37-3	5373-5385	preprocessed	_
37-4	5386-5391	using	_
37-5	5392-5396	SPM8	_
37-6	5397-5398	(	_
37-7	5399-5407	Wellcome	_
37-8	5408-5418	Department	_
37-9	5419-5421	of	_
37-10	5422-5431	Cognitive	_
37-11	5432-5441	Neurology	_
37-12	5442-5443	,	_
37-13	5444-5450	London	_
37-14	5451-5452	,	_
37-15	5453-5455	UK	_
37-16	5456-5457	)	_
37-17	5458-5459	,	_
37-18	5460-5469	including	_
37-19	5470-5480	correction	_
37-20	5481-5484	for	_
37-21	5485-5490	slice	_
37-22	5491-5495	time	_
37-23	5496-5499	and	_
37-24	5500-5504	head	_
37-25	5505-5511	motion	_
37-26	5512-5513	.	_

38-1	5514-5524	Functional	_
38-2	5525-5532	volumes	_
38-3	5533-5537	were	_
38-4	5538-5547	realigned	_
38-5	5548-5550	to	_
38-6	5551-5554	the	_
38-7	5555-5565	anatomical	_
38-8	5566-5571	image	_
38-9	5572-5573	,	_
38-10	5574-5583	spatially	_
38-11	5584-5594	normalized	_
38-12	5595-5597	to	_
38-13	5598-5601	the	_
38-14	5602-5610	Montreal	_
38-15	5611-5623	Neurological	_
38-16	5624-5633	Institute	_
38-17	5634-5635	(	_
38-18	5636-5639	MNI	_
38-19	5640-5641	)	_
38-20	5642-5650	template	_
38-21	5651-5652	,	_
38-22	5653-5656	and	_
38-23	5657-5665	smoothed	_
38-24	5666-5670	with	_
38-25	5671-5672	a	_
38-26	5673-5674	6	_
38-27	5675-5677	mm	_
38-28	5678-5686	Gaussian	_
38-29	5687-5693	kernel	_
38-30	5694-5695	.	_

39-1	5696-5700	fMRI	_
39-2	5701-5709	analyses	_
39-3	5710-5718	Analyses	_
39-4	5719-5723	were	_
39-5	5724-5733	conducted	_
39-6	5734-5736	in	_
39-7	5737-5745	Neuroelf	_
39-8	5746-5747	(	_
39-9	5748-5764	www.neuroelf.net	_
39-10	5765-5766	)	_
39-11	5767-5772	using	_
39-12	5773-5780	general	_
39-13	5781-5787	linear	_
39-14	5788-5794	models	_
39-15	5795-5796	(	_
39-16	5797-5801	GLMs	_
39-17	5802-5803	)	_
39-18	5804-5806	in	_
39-19	5807-5812	which	_
39-20	5813-5819	events	_
39-21	5820-5824	were	_
39-22	5825-5834	convolved	_
39-23	5835-5839	with	_
39-24	5840-5849	canonical	_
39-25	5850-5861	hemodynamic	_
39-26	5862-5870	response	_
39-27	5871-5880	functions	_
39-28	5881-5882	.	_

40-1	5883-5885	We	_
40-2	5886-5894	included	_
40-3	5895-5901	motion	_
40-4	5902-5912	parameters	_
40-5	5913-5916	and	_
40-6	5917-5918	a	_
40-7	5919-5928	high-pass	_
40-8	5929-5935	filter	_
40-9	5936-5938	of	_
40-10	5939-5942	128	_
40-11	5943-5944	s	_
40-12	5945-5947	as	_
40-13	5948-5958	regressors	_
40-14	5959-5961	of	_
40-15	5962-5964	no	_
40-16	5965-5973	interest	_
40-17	5974-5976	to	_
40-18	5977-5990	statistically	_
40-19	5991-5997	remove	_
40-20	5998-6002	head	_
40-21	6003-6009	motion	_
40-22	6010-6014	from	_
40-23	6015-6023	measures	_
40-24	6024-6026	of	_
40-25	6027-6032	brain	_
40-26	6033-6041	activity	_
40-27	6042-6043	.	_

41-1	6044-6052	Analyses	_
41-2	6053-6060	focused	_
41-3	6061-6063	on	_
41-4	6064-6067	the	_
41-5	6068-6071	6-s	_
41-6	6072-6077	pause	_
41-7	6078-6084	period	_
41-8	6085-6092	between	_
41-9	6093-6102	listening	_
41-10	6103-6106	and	_
41-11	6107-6113	rating	_
41-12	6114-6116	to	_
41-13	6117-6123	assess	_
41-14	6124-6130	neural	_
41-15	6131-6139	activity	_
41-16	6140-6149	following	_
41-17	6150-6157	periods	_
41-18	6158-6160	of	_
41-19	6161-6169	critical	_
41-20	6170-6171	,	_
41-21	6172-6179	neutral	_
41-22	6180-6181	,	_
41-23	6182-6184	or	_
41-24	6185-6193	praising	_
41-25	6194-6200	social	_
41-26	6201-6212	experiences	_
41-27	6213-6214	(	_
41-28	6215-6219	i.e.	_
41-29	6220-6221	,	_
41-30	6222-6225	the	_
41-31	6226-6230	time	_
41-32	6231-6233	at	_
41-33	6234-6239	which	_
41-34	6240-6252	participants	_
41-35	6253-6258	would	_
41-36	6259-6261	be	_
41-37	6262-6272	processing	_
41-38	6273-6276	the	_
41-39	6277-6285	emotions	_
41-40	6286-6293	aroused	_
41-41	6294-6300	during	_
41-42	6301-6304	the	_
41-43	6305-6314	listening	_
41-44	6315-6321	period	_
41-45	6322-6323	)	_
41-46	6324-6325	.	_

42-1	6326-6330	GLMs	_
42-2	6331-6339	included	_
42-3	6340-6349	listening	_
42-4	6350-6357	periods	_
42-5	6358-6363	split	_
42-6	6364-6366	by	_
42-7	6367-6376	condition	_
42-8	6377-6380	and	_
42-9	6381-6387	rating	_
42-10	6388-6395	periods	_
42-11	6396-6398	as	_
42-12	6399-6409	regressors	_
42-13	6410-6412	of	_
42-14	6413-6415	no	_
42-15	6416-6424	interest	_
42-16	6425-6427	to	_
42-17	6428-6434	ensure	_
42-18	6435-6439	that	_
42-19	6440-6444	only	_
42-20	6445-6448	the	_
42-21	6449-6460	inter-trial	_
42-22	6461-6469	interval	_
42-23	6470-6473	was	_
42-24	6474-6481	treated	_
42-25	6482-6484	as	_
42-26	6485-6493	baseline	_
42-27	6494-6495	.	_

43-1	6496-6499	Our	_
43-2	6500-6507	primary	_
43-3	6508-6512	fMRI	_
43-4	6513-6521	analysis	_
43-5	6522-6530	examined	_
43-6	6531-6536	group	_
43-7	6537-6548	differences	_
43-8	6549-6551	in	_
43-9	6552-6558	neural	_
43-10	6559-6567	activity	_
43-11	6568-6577	following	_
43-12	6578-6586	critical	_
43-13	6587-6595	comments	_
43-14	6596-6604	compared	_
43-15	6605-6607	to	_
43-16	6608-6615	neutral	_
43-17	6616-6624	comments	_
43-18	6625-6626	[	_
43-19	6627-6631	i.e.	_
43-20	6632-6633	,	_
43-21	6634-6642	critical	_
43-22	6643-6644	>	_
43-23	6645-6652	neutral	_
43-24	6653-6654	(	_
43-25	6655-6662	non-FHR	_
43-26	6663-6664	>	_
43-27	6665-6668	FHR	_
43-28	6669-6670	)	_
43-29	6671-6672	]	_
43-30	6673-6674	.	_

44-1	6675-6679	This	_
44-2	6680-6688	contrast	_
44-3	6689-6697	examined	_
44-4	6698-6704	neural	_
44-5	6705-6713	activity	_
44-6	6714-6719	while	_
44-7	6720-6732	participants	_
44-8	6733-6742	processed	_
44-9	6743-6751	emotions	_
44-10	6752-6759	aroused	_
44-11	6760-6762	by	_
44-12	6763-6771	critical	_
44-13	6772-6780	comments	_
44-14	6781-6784	and	_
44-15	6785-6789	used	_
44-16	6790-6793	the	_
44-17	6794-6801	neutral	_
44-18	6802-6811	condition	_
44-19	6812-6814	to	_
44-20	6815-6822	control	_
44-21	6823-6826	for	_
44-22	6827-6836	low-level	_
44-23	6837-6841	task	_
44-24	6842-6850	features	_
44-25	6851-6852	.	_

45-1	6853-6858	Given	_
45-2	6859-6863	that	_
45-3	6864-6872	previous	_
45-4	6873-6881	research	_
45-5	6882-6893	establishes	_
45-6	6894-6898	that	_
45-7	6899-6902	the	_
45-8	6903-6908	DLPFC	_
45-9	6909-6914	plays	_
45-10	6915-6916	a	_
45-11	6917-6925	critical	_
45-12	6926-6930	role	_
45-13	6931-6933	in	_
45-14	6934-6941	emotion	_
45-15	6942-6952	regulation	_
45-16	6953-6956	and	_
45-17	6957-6961	that	_
45-18	6962-6967	DLPFC	_
45-19	6968-6976	activity	_
45-20	6977-6979	is	_
45-21	6980-6988	atypical	_
45-22	6989-6991	in	_
45-23	6992-6995	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
45-24	6996-7007	individuals	_
45-25	7008-7009	,	_
45-26	7010-7012	we	_
45-27	7013-7016	had	_
45-28	7017-7019	an	_
45-29	7020-7021	a	_
45-30	7022-7028	priori	_
45-31	7029-7037	interest	_
45-32	7038-7040	in	_
45-33	7041-7050	exploring	_
45-34	7051-7056	group	_
45-35	7057-7068	differences	_
45-36	7069-7071	in	_
45-37	7072-7076	this	_
45-38	7077-7083	region	_
45-39	7084-7085	.	_

46-1	7086-7091	Hence	_
46-2	7092-7093	,	_
46-3	7094-7096	we	_
46-4	7097-7106	corrected	_
46-5	7107-7111	fMRI	_
46-6	7112-7120	analyses	_
46-7	7121-7124	for	_
46-8	7125-7133	multiple	_
46-9	7134-7145	comparisons	_
46-10	7146-7151	using	_
46-11	7152-7154	an	_
46-12	7155-7168	independently	_
46-13	7169-7176	defined	_
46-14	7177-7186	bilateral	_
46-15	7187-7192	DLPFC	_
46-16	7193-7197	mask	_
46-17	7198-7202	from	_
46-18	7203-7204	.	_

47-1	7205-7207	We	_
47-2	7208-7215	applied	_
47-3	7216-7228	small-volume	_
47-4	7229-7239	correction	_
47-5	7240-7246	within	_
47-6	7247-7251	this	_
47-7	7252-7261	bilateral	_
47-8	7262-7267	DLPFC	_
47-9	7268-7272	mask	_
47-10	7273-7275	to	_
47-11	7276-7282	ensure	_
47-12	7283-7287	that	_
47-13	7288-7299	significant	_
47-14	7300-7308	clusters	_
47-15	7309-7315	within	_
47-16	7316-7319	the	_
47-17	7320-7325	DLPFC	_
47-18	7326-7329	met	_
47-19	7330-7331	a	_
47-20	7332-7341	corrected	_
47-21	7342-7351	threshold	_
47-22	7352-7354	of	_
47-23	7355-7356	p	_
47-24	7357-7358	<	_
47-25	7359-7362	.05	_
47-26	7363-7364	.	_

48-1	7365-7368	For	_
48-2	7369-7381	completeness	_
48-3	7382-7383	,	_
48-4	7384-7386	we	_
48-5	7387-7391	also	_
48-6	7392-7398	report	_
48-7	7399-7406	regions	_
48-8	7407-7411	from	_
48-9	7412-7423	whole-brain	_
48-10	7424-7433	contrasts	_
48-11	7434-7438	that	_
48-12	7439-7447	occurred	_
48-13	7448-7455	outside	_
48-14	7456-7459	the	_
48-15	7460-7465	DLPFC	_
48-16	7466-7467	.	_

49-1	7468-7470	To	_
49-2	7471-7478	correct	_
49-3	7479-7482	for	_
49-4	7483-7491	multiple	_
49-5	7492-7503	comparisons	_
49-6	7504-7511	outside	_
49-7	7512-7514	of	_
49-8	7515-7518	the	_
49-9	7519-7524	DLPFC	_
49-10	7525-7526	,	_
49-11	7527-7529	we	_
49-12	7530-7534	used	_
49-13	7535-7536	a	_
49-14	7537-7542	Monte	_
49-15	7543-7548	Carlo	_
49-16	7549-7559	simulation	_
49-17	7560-7571	implemented	_
49-18	7572-7575	via	_
49-19	7576-7584	Neuroelf	_
49-20	7585-7587	's	_
49-21	7588-7596	Alphasim	_
49-22	7597-7605	function	_
49-23	7606-7608	to	_
49-24	7609-7618	determine	_
49-25	7619-7622	the	_
49-26	7623-7630	minimum	_
49-27	7631-7638	cluster	_
49-28	7639-7643	size	_
49-29	7644-7648	that	_
49-30	7649-7654	would	_
49-31	7655-7657	be	_
49-32	7658-7666	required	_
49-33	7667-7669	to	_
49-34	7670-7674	meet	_
49-35	7675-7676	a	_
49-36	7677-7686	corrected	_
49-37	7687-7696	threshold	_
49-38	7697-7699	of	_
49-39	7700-7701	p	_
49-40	7702-7703	<	_
49-41	7704-7707	.05	_
49-42	7708-7709	.	_

50-1	7710-7713	The	_
50-2	7714-7722	Alphasim	_
50-3	7723-7733	simulation	_
50-4	7734-7743	concluded	_
50-5	7744-7748	that	_
50-6	7749-7750	a	_
50-7	7751-7758	minimum	_
50-8	7759-7761	of	_
50-9	7762-7764	39	_
50-10	7765-7775	contiguous	_
50-11	7776-7782	voxels	_
50-12	7783-7785	at	_
50-13	7786-7787	a	_
50-14	7788-7798	voxel-wise	_
50-15	7799-7808	threshold	_
50-16	7809-7811	of	_
50-17	7812-7813	p	_
50-18	7814-7815	<	_
50-19	7816-7820	.001	_
50-20	7821-7824	met	_
50-21	7825-7829	this	_
50-22	7830-7839	corrected	_
50-23	7840-7849	threshold	_
50-24	7850-7851	.	_

51-1	7852-7857	Hence	_
51-2	7858-7859	,	_
51-3	7860-7862	we	_
51-4	7863-7869	report	_
51-5	7870-7878	clusters	_
51-6	7879-7883	that	_
51-7	7884-7888	meet	_
51-8	7889-7890	a	_
51-9	7891-7892	p	_
51-10	7893-7894	<	_
51-11	7895-7898	.05	_
51-12	7899-7908	threshold	_
51-13	7909-7910	,	_
51-14	7911-7917	either	_
51-15	7918-7927	corrected	_
51-16	7928-7933	using	_
51-17	7934-7946	small-volume	_
51-18	7947-7957	correction	_
51-19	7958-7959	(	_
51-20	7960-7966	within	_
51-21	7967-7970	the	_
51-22	7971-7976	DLPFC	_
51-23	7977-7978	)	_
51-24	7979-7981	or	_
51-25	7982-7990	Alphasim	_
51-26	7991-8001	correction	_
51-27	8002-8003	(	_
51-28	8004-8011	outside	_
51-29	8012-8015	the	_
51-30	8016-8021	DLPFC	_
51-31	8022-8023	)	_
51-32	8024-8025	.	_

52-1	8026-8039	Independently	_
52-2	8040-8047	defined	_
52-3	8048-8066	region-of-interest	_
52-4	8067-8068	(	_
52-5	8069-8072	ROI	_
52-6	8073-8074	)	_
52-7	8075-8083	analyses	_
52-8	8084-8087	can	_
52-9	8088-8095	provide	_
52-10	8096-8109	corroborating	_
52-11	8110-8118	evidence	_
52-12	8119-8122	for	_
52-13	8123-8134	whole-brain	_
52-14	8135-8143	analyses	_
52-15	8144-8147	and	_
52-16	8148-8151	can	_
52-17	8152-8159	further	_
52-18	8160-8169	establish	_
52-19	8170-8174	that	_
52-20	8175-8183	specific	_
52-21	8184-8191	regions	_
52-22	8192-8195	are	_
52-23	8196-8206	implicated	_
52-24	8207-8209	in	_
52-25	8210-8217	certain	_
52-26	8218-8231	psychological	_
52-27	8232-8241	processes	_
52-28	8242-8243	.	_

53-1	8244-8248	Thus	_
53-2	8249-8250	,	_
53-3	8251-8253	as	_
53-4	8254-8256	in	_
53-5	8257-8261	this	_
53-6	8262-8267	prior	_
53-7	8268-8272	work	_
53-8	8273-8274	,	_
53-9	8275-8277	we	_
53-10	8278-8282	used	_
53-11	8283-8293	Neurosynth	_
53-12	8294-8296	to	_
53-13	8297-8305	identify	_
53-14	8306-8311	brain	_
53-15	8312-8319	regions	_
53-16	8320-8324	from	_
53-17	8325-8328	the	_
53-18	8329-8341	neuroimaging	_
53-19	8342-8352	literature	_
53-20	8353-8357	that	_
53-21	8358-8362	show	_
53-22	8363-8364	a	_
53-23	8365-8376	significant	_
53-24	8377-8390	meta-analytic	_
53-25	8391-8402	association	_
53-26	8403-8407	with	_
53-27	8408-8411	the	_
53-28	8412-8418	phrase	_
53-29	8419-8420	“	_
53-30	8421-8428	emotion	_
53-31	8429-8439	regulation	_
53-32	8440-8441	”	_
53-33	8442-8443	.	_

54-1	8444-8445	A	_
54-2	8446-8459	meta-analysis	_
54-3	8460-8462	of	_
54-4	8463-8466	134	_
54-5	8467-8479	neuroimaging	_
54-6	8480-8487	studies	_
54-7	8488-8496	returned	_
54-8	8497-8509	significant1	_
54-9	8510-8518	clusters	_
54-10	8519-8521	in	_
54-11	8522-8525	the	_
54-12	8526-8530	left	_
54-13	8531-8536	DLPFC	_
54-14	8537-8538	(	_
54-15	8539-8542	MNI	_
54-16	8543-8554	coordinates	_
54-17	8555-8556	=	_
54-18	8557-8558	[	_
54-19	8559-8562	−40	_
54-20	8563-8564	,	_
54-21	8565-8567	16	_
54-22	8568-8569	,	_
54-23	8570-8572	44	_
54-24	8573-8574	]	_
54-25	8575-8576	;	_
54-26	8577-8578	k	_
54-27	8579-8580	=	_
54-28	8581-8584	192	_
54-29	8585-8586	)	_
54-30	8587-8590	and	_
54-31	8591-8596	right	_
54-32	8597-8602	DLPFC	_
54-33	8603-8604	(	_
54-34	8605-8616	coordinates	_
54-35	8617-8618	=	_
54-36	8619-8620	[	_
54-37	8621-8623	36	_
54-38	8624-8625	,	_
54-39	8626-8628	24	_
54-40	8629-8630	,	_
54-41	8631-8633	46	_
54-42	8634-8635	]	_
54-43	8636-8637	;	_
54-44	8638-8639	k	_
54-45	8640-8641	=	_
54-46	8642-8644	50	_
54-47	8645-8646	)	_
54-48	8647-8648	.	_

55-1	8649-8651	We	_
55-2	8652-8661	extracted	_
55-3	8662-8666	beta	_
55-4	8667-8676	estimates	_
55-5	8677-8679	of	_
55-6	8680-8688	activity	_
55-7	8689-8691	in	_
55-8	8692-8697	these	_
55-9	8698-8706	clusters	_
55-10	8707-8713	during	_
55-11	8714-8717	the	_
55-12	8718-8727	expressed	_
55-13	8728-8735	emotion	_
55-14	8736-8740	task	_
55-15	8741-8744	and	_
55-16	8745-8753	computed	_
55-17	8754-8762	critical	_
55-18	8763-8764	>	_
55-19	8765-8772	neutral	_
55-20	8773-8783	difference	_
55-21	8784-8790	scores	_
55-22	8791-8794	for	_
55-23	8795-8799	each	_
55-24	8800-8811	participant	_
55-25	8812-8813	.	_

56-1	8814-8816	We	_
56-2	8817-8823	tested	_
56-3	8824-8827	for	_
56-4	8828-8833	group	_
56-5	8834-8845	differences	_
56-6	8846-8848	in	_
56-7	8849-8854	these	_
56-8	8855-8868	independently	_
56-9	8869-8876	defined	_
56-10	8877-8881	ROIs	_
56-11	8882-8887	using	_
56-12	8888-8895	t-tests	_
56-13	8896-8897	.	_

57-1	8898-8902	This	_
57-2	8903-8906	ROI	_
57-3	8907-8915	analysis	_
57-4	8916-8926	buttressed	_
57-5	8927-8938	conclusions	_
57-6	8939-8943	from	_
57-7	8944-8947	the	_
57-8	8948-8960	small-volume	_
57-9	8961-8970	corrected	_
57-10	8971-8982	whole-brain	_
57-11	8983-8991	analysis	_
57-12	8992-9001	discussed	_
57-13	9002-9007	above	_
57-14	9008-9011	and	_
57-15	9012-9019	ensured	_
57-16	9020-9024	that	_
57-17	9025-9028	the	_
57-18	9029-9037	specific	_
57-19	9038-9045	portion	_
57-20	9046-9048	of	_
57-21	9049-9052	the	_
57-22	9053-9058	DLPFC	_
57-23	9059-9061	we	_
57-24	9062-9070	analyzed	_
57-25	9071-9074	was	_
57-26	9075-9085	associated	_
57-27	9086-9090	with	_
57-28	9091-9098	emotion	_
57-29	9099-9109	regulation	_
57-30	9110-9112	in	_
57-31	9113-9118	prior	_
57-32	9119-9126	studies	_
57-33	9127-9128	.	_

58-1	9129-9140	Daily-diary	_
58-2	9141-9149	measures	_
58-3	9150-9162	Participants	_
58-4	9163-9172	completed	_
58-5	9173-9175	an	_
58-6	9176-9182	online	_
58-7	9183-9196	questionnaire	_
58-8	9197-9201	each	_
58-9	9202-9209	evening	_
58-10	9210-9216	before	_
58-11	9217-9220	bed	_
58-12	9221-9224	for	_
58-13	9225-9227	28	_
58-14	9228-9232	days	_
58-15	9233-9242	following	_
58-16	9243-9246	the	_
58-17	9247-9250	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
58-18	9251-9255	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
58-19	9256-9257	(	_
58-20	9258-9261	see	_
58-21	9262-9267	Table	_
58-22	9268-9269	2	_
58-23	9270-9273	for	_
58-24	9274-9285	daily-diary	_
58-25	9286-9295	questions	_
58-26	9296-9297	,	_
58-27	9298-9306	Cronbach	_
58-28	9307-9309	's	_
58-29	9310-9312	αs	_
58-30	9313-9314	,	_
58-31	9315-9326	descriptive	_
58-32	9327-9337	statistics	_
58-33	9338-9339	,	_
58-34	9340-9343	and	_
58-35	9344-9349	group	_
58-36	9350-9361	comparisons	_
58-37	9362-9363	)	_
58-38	9364-9365	.	_

59-1	9366-9370	Each	_
59-2	9371-9374	day	_
59-3	9375-9376	,	_
59-4	9377-9389	participants	_
59-5	9390-9399	indicated	_
59-6	9400-9403	how	_
59-7	9404-9408	much	_
59-8	9409-9413	they	_
59-9	9414-9418	felt	_
59-10	9419-9420	a	_
59-11	9421-9427	series	_
59-12	9428-9430	of	_
59-13	9431-9439	emotions	_
59-14	9440-9441	(	_
59-15	9442-9446	e.g.	_
59-16	9447-9448	,	_
59-17	9449-9456	anxious	_
59-18	9457-9458	,	_
59-19	9459-9462	sad	_
59-20	9463-9464	,	_
59-21	9465-9473	hopeless	_
59-22	9474-9475	,	_
59-23	9476-9484	cheerful	_
59-24	9485-9486	,	_
59-25	9487-9492	happy	_
59-26	9493-9494	,	_
59-27	9495-9497	or	_
59-28	9498-9505	content	_
59-29	9506-9507	)	_
59-30	9508-9510	on	_
59-31	9511-9518	5-point	_
59-32	9519-9525	scales	_
59-33	9526-9527	(	_
59-34	9528-9529	1	_
59-35	9530-9531	=	_
59-36	9532-9535	not	_
59-37	9536-9538	at	_
59-38	9539-9542	all	_
59-39	9543-9544	,	_
59-40	9545-9546	5	_
59-41	9547-9548	=	_
59-42	9549-9558	extremely	_
59-43	9559-9560	)	_
59-44	9561-9562	.	_

60-1	9563-9565	We	_
60-2	9566-9574	averaged	_
60-3	9575-9583	negative	_
60-4	9584-9587	and	_
60-5	9588-9596	positive	_
60-6	9597-9604	emotion	_
60-7	9605-9612	ratings	_
60-8	9613-9615	to	_
60-9	9616-9623	produce	_
60-10	9624-9629	daily	_
60-11	9630-9638	measures	_
60-12	9639-9641	of	_
60-13	9642-9650	negative	_
60-14	9651-9654	and	_
60-15	9655-9663	positive	_
60-16	9664-9668	mood	_
60-17	9669-9670	.	_

61-1	9671-9683	Participants	_
61-2	9684-9688	also	_
61-3	9689-9698	indicated	_
61-4	9699-9706	whether	_
61-5	9707-9709	or	_
61-6	9710-9713	not	_
61-7	9714-9718	they	_
61-8	9719-9722	had	_
61-9	9723-9734	experienced	_
61-10	9735-9736	7	_
61-11	9737-9742	forms	_
61-12	9743-9745	of	_
61-13	9746-9759	interpersonal	_
61-14	9760-9768	conflict	_
61-15	9769-9773	that	_
61-16	9774-9777	day	_
61-17	9778-9779	(	_
61-18	9780-9784	e.g.	_
61-19	9785-9786	,	_
61-20	9787-9788	“	_
61-21	9789-9790	I	_
61-22	9791-9795	felt	_
61-23	9796-9800	that	_
61-24	9801-9808	someone	_
61-25	9809-9813	else	_
61-26	9814-9817	was	_
61-27	9818-9825	hostile	_
61-28	9826-9833	towards	_
61-29	9834-9836	me	_
61-30	9837-9838	”	_
61-31	9839-9840	)	_
61-32	9841-9842	,	_
61-33	9843-9846	and	_
61-34	9847-9851	they	_
61-35	9852-9857	rated	_
61-36	9858-9861	how	_
61-37	9862-9873	distressing	_
61-38	9874-9878	they	_
61-39	9879-9884	found	_
61-40	9885-9889	each	_
61-41	9890-9898	conflict	_
61-42	9899-9900	(	_
61-43	9901-9902	1	_
61-44	9903-9904	=	_
61-45	9905-9908	not	_
61-46	9909-9911	at	_
61-47	9912-9915	all	_
61-48	9916-9917	,	_
61-49	9918-9919	5	_
61-50	9920-9921	=	_
61-51	9922-9931	extremely	_
61-52	9932-9933	)	_
61-53	9934-9935	.	_

62-1	9936-9938	We	_
62-2	9939-9947	computed	_
62-3	9948-9951	the	_
62-4	9952-9959	maximum	_
62-5	9960-9968	conflict	_
62-6	9969-9977	distress	_
62-7	9978-9981	for	_
62-8	9982-9986	each	_
62-9	9987-9990	day	_
62-10	9991-9992	(	_
62-11	9993-9994	0	_
62-12	9995-9997	if	_
62-13	9998-10000	no	_
62-14	10001-10010	conflicts	_
62-15	10011-10015	that	_
62-16	10016-10019	day	_
62-17	10020-10021	)	_
62-18	10022-10023	.	_

63-1	10024-10031	Finally	_
63-2	10032-10033	,	_
63-3	10034-10046	participants	_
63-4	10047-10056	completed	_
63-5	10057-10058	a	_
63-6	10059-10062	set	_
63-7	10063-10065	of	_
63-8	10066-10075	questions	_
63-9	10076-10080	that	_
63-10	10081-10089	measured	_
63-11	10090-10094	each	_
63-12	10095-10098	day	_
63-13	10099-10101	's	_
63-14	10102-10107	level	_
63-15	10108-10110	of	_
63-16	10111-10119	negative	_
63-17	10120-10128	symptoms	_
63-18	10129-10130	(	_
63-19	10131-10135	e.g.	_
63-20	10136-10137	,	_
63-21	10138-10139	“	_
63-22	10140-10141	I	_
63-23	10142-10146	felt	_
63-24	10147-10151	like	_
63-25	10152-10153	I	_
63-26	10154-10157	did	_
63-27	10158-10161	n't	_
63-28	10162-10166	care	_
63-29	10167-10172	about	_
63-30	10173-10181	anything	_
63-31	10182-10183	”	_
63-32	10184-10185	)	_
63-33	10186-10187	,	_
63-34	10188-10196	positive	_
63-35	10197-10205	symptoms	_
63-36	10206-10207	(	_
63-37	10208-10212	e.g.	_
63-38	10213-10214	,	_
63-39	10215-10216	“	_
63-40	10217-10218	I	_
63-41	10219-10223	felt	_
63-42	10224-10226	as	_
63-43	10227-10229	if	_
63-44	10230-10237	someone	_
63-45	10238-10242	else	_
63-46	10243-10248	could	_
63-47	10249-10253	read	_
63-48	10254-10256	my	_
63-49	10257-10265	thoughts	_
63-50	10266-10269	and	_
63-51	10270-10278	feelings	_
63-52	10279-10280	”	_
63-53	10281-10282	)	_
63-54	10283-10284	,	_
63-55	10285-10288	and	_
63-56	10289-10301	disorganized	_
63-57	10302-10310	symptoms	_
63-58	10311-10312	(	_
63-59	10313-10317	e.g.	_
63-60	10318-10319	,	_
63-61	10320-10321	“	_
63-62	10322-10323	I	_
63-63	10324-10328	felt	_
63-64	10329-10333	like	_
63-65	10334-10336	my	_
63-66	10337-10345	thoughts	_
63-67	10346-10350	were	_
63-68	10351-10358	jumbled	_
63-69	10359-10360	”	_
63-70	10361-10362	)	_
63-71	10363-10368	again	_
63-72	10369-10371	on	_
63-73	10372-10379	5-point	_
63-74	10380-10386	scales	_
63-75	10387-10388	(	_
63-76	10389-10390	1	_
63-77	10391-10392	=	_
63-78	10393-10396	not	_
63-79	10397-10399	at	_
63-80	10400-10403	all	_
63-81	10404-10405	,	_
63-82	10406-10407	5	_
63-83	10408-10409	=	_
63-84	10410-10419	extremely	_
63-85	10420-10421	)	_
63-86	10422-10423	.	_

64-1	10424-10426	We	_
64-2	10427-10435	computed	_
64-3	10436-10440	each	_
64-4	10441-10444	day	_
64-5	10445-10447	's	_
64-6	10448-10455	average	_
64-7	10456-10462	rating	_
64-8	10463-10465	of	_
64-9	10466-10470	each	_
64-10	10471-10478	symptom	_
64-11	10479-10483	type	_
64-12	10484-10485	.	_

65-1	10486-10493	Because	_
65-2	10494-10505	reliability	_
65-3	10506-10509	for	_
65-4	10510-10513	our	_
65-5	10514-10521	measure	_
65-6	10522-10524	of	_
65-7	10525-10537	disorganized	_
65-8	10538-10546	symptoms	_
65-9	10547-10550	was	_
65-10	10551-10565	unsatisfactory	_
65-11	10566-10567	,	_
65-12	10568-10576	Cronbach	_
65-13	10577-10579	's	_
65-14	10580-10581	α	_
65-15	10582-10583	=	_
65-16	10584-10587	.48	_
65-17	10588-10589	,	_
65-18	10590-10592	we	_
65-19	10593-10601	excluded	_
65-20	10602-10604	it	_
65-21	10605-10609	from	_
65-22	10610-10617	further	_
65-23	10618-10626	analyses	_
65-24	10627-10628	.	_

66-1	10629-10631	We	_
66-2	10632-10636	also	_
66-3	10637-10645	excluded	_
66-4	10646-10651	diary	_
66-5	10652-10659	entries	_
66-6	10660-10664	that	_
66-7	10665-10669	were	_
66-8	10670-10680	incomplete	_
66-9	10681-10683	or	_
66-10	10684-10688	were	_
66-11	10689-10698	completed	_
66-12	10699-10702	the	_
66-13	10703-10712	following	_
66-14	10713-10720	morning	_
66-15	10721-10722	.	_

67-1	10723-10734	Daily-diary	_
67-2	10735-10743	analyses	_
67-3	10744-10746	We	_
67-4	10747-10752	first	_
67-5	10753-10765	investigated	_
67-6	10766-10773	whether	_
67-7	10774-10786	participants	_
67-8	10787-10788	'	_
67-9	10789-10795	neural	_
67-10	10796-10805	responses	_
67-11	10806-10808	to	_
67-12	10809-10817	critical	_
67-13	10818-10826	comments	_
67-14	10827-10836	predicted	_
67-15	10837-10842	their	_
67-16	10843-10847	mood	_
67-17	10848-10851	and	_
67-18	10852-10860	symptoms	_
67-19	10861-10863	on	_
67-20	10864-10868	days	_
67-21	10869-10873	with	_
67-22	10874-10885	distressing	_
67-23	10886-10892	social	_
67-24	10893-10902	conflicts	_
67-25	10903-10904	.	_

68-1	10905-10914	Following	_
68-2	10915-10923	previous	_
68-3	10924-10928	work	_
68-4	10929-10930	,	_
68-5	10931-10933	we	_
68-6	10934-10943	extracted	_
68-7	10944-10948	beta	_
68-8	10949-10958	estimates	_
68-9	10959-10961	of	_
68-10	10962-10968	neural	_
68-11	10969-10977	activity	_
68-12	10978-10980	in	_
68-13	10981-10984	the	_
68-14	10985-10994	expressed	_
68-15	10995-11002	emotion	_
68-16	11003-11007	task	_
68-17	11008-11011	and	_
68-18	11012-11020	examined	_
68-19	11021-11028	whether	_
68-20	11029-11033	this	_
68-21	11034-11044	interacted	_
68-22	11045-11049	with	_
68-23	11050-11053	FHR	_
68-24	11054-11060	status	_
68-25	11061-11067	and/or	_
68-26	11068-11078	real-world	_
68-27	11079-11085	social	_
68-28	11086-11094	conflict	_
68-29	11095-11097	to	_
68-30	11098-11105	predict	_
68-31	11106-11111	daily	_
68-32	11112-11116	mood	_
68-33	11117-11120	and	_
68-34	11121-11129	symptoms	_
68-35	11130-11132	in	_
68-36	11133-11134	a	_
68-37	11135-11141	series	_
68-38	11142-11144	of	_
68-39	11145-11158	mixed-effects	_
68-40	11159-11165	models	_
68-41	11166-11167	.	_

69-1	11168-11170	We	_
69-2	11171-11175	used	_
69-3	11176-11182	neural	_
69-4	11183-11191	activity	_
69-5	11192-11196	from	_
69-6	11197-11200	the	_
69-7	11201-11211	Neurosynth	_
69-8	11212-11216	ROIs	_
69-9	11217-11219	in	_
69-10	11220-11225	these	_
69-11	11226-11241	analyses—rather	_
69-12	11242-11246	than	_
69-13	11247-11255	activity	_
69-14	11256-11258	in	_
69-15	11259-11267	clusters	_
69-16	11268-11278	identified	_
69-17	11279-11281	in	_
69-18	11282-11285	the	_
69-19	11286-11297	whole-brain	_
69-20	11298-11309	analysis—to	_
69-21	11310-11315	avoid	_
69-22	11316-11321	using	_
69-23	11322-11326	data	_
69-24	11327-11331	that	_
69-25	11332-11335	had	_
69-26	11336-11340	been	_
69-27	11341-11349	selected	_
69-28	11350-11355	based	_
69-29	11356-11358	on	_
69-30	11359-11364	group	_
69-31	11365-11376	differences	_
69-32	11377-11378	.	_

70-1	11379-11386	Because	_
70-2	11387-11392	DLPFC	_
70-3	11393-11398	betas	_
70-4	11399-11403	from	_
70-5	11404-11407	the	_
70-6	11408-11412	left	_
70-7	11413-11416	and	_
70-8	11417-11422	right	_
70-9	11423-11427	ROIs	_
70-10	11428-11432	were	_
70-11	11433-11441	strongly	_
70-12	11442-11452	correlated	_
70-13	11453-11454	,	_
70-14	11455-11456	r	_
70-15	11457-11458	=	_
70-16	11459-11463	0.52	_
70-17	11464-11465	,	_
70-18	11466-11467	p	_
70-19	11468-11469	=	_
70-20	11470-11474	.001	_
70-21	11475-11476	,	_
70-22	11477-11479	we	_
70-23	11480-11488	averaged	_
70-24	11489-11494	these	_
70-25	11495-11499	into	_
70-26	11500-11501	a	_
70-27	11502-11508	single	_
70-28	11509-11518	bilateral	_
70-29	11519-11524	DLPFC	_
70-30	11525-11533	estimate	_
70-31	11534-11537	for	_
70-32	11538-11542	each	_
70-33	11543-11554	participant	_
70-34	11555-11556	.	_

71-1	11557-11559	We	_
71-2	11560-11564	used	_
71-3	11565-11568	two	_
71-4	11569-11573	sets	_
71-5	11574-11576	of	_
71-6	11577-11590	mixed-effects	_
71-7	11591-11597	models	_
71-8	11598-11600	to	_
71-9	11601-11605	test	_
71-10	11606-11609	the	_
71-11	11610-11620	hypothesis	_
71-12	11621-11625	that	_
71-13	11626-11632	weaker	_
71-14	11633-11638	DLPFC	_
71-15	11639-11648	responses	_
71-16	11649-11651	to	_
71-17	11652-11661	criticism	_
71-18	11662-11664	in	_
71-19	11665-11668	FHR	_
71-20	11669-11680	individuals	_
71-21	11681-11685	were	_
71-22	11686-11696	associated	_
71-23	11697-11701	with	_
71-24	11702-11711	increased	_
71-25	11712-11720	negative	_
71-26	11721-11725	mood	_
71-27	11726-11729	and	_
71-28	11730-11744	psychotic-like	_
71-29	11745-11753	symptoms	_
71-30	11754-11763	following	_
71-31	11764-11774	real-world	_
71-32	11775-11781	social	_
71-33	11782-11790	conflict	_
71-34	11791-11792	.	_

72-1	11793-11796	The	_
72-2	11797-11802	first	_
72-3	11803-11806	set	_
72-4	11807-11809	of	_
72-5	11810-11816	models	_
72-6	11817-11825	examined	_
72-7	11826-11829	how	_
72-8	11830-11835	DLPFC	_
72-9	11836-11844	activity	_
72-10	11845-11846	,	_
72-11	11847-11850	FHR	_
72-12	11851-11857	status	_
72-13	11858-11859	,	_
72-14	11860-11868	same-day	_
72-15	11869-11877	conflict	_
72-16	11878-11886	distress	_
72-17	11887-11888	,	_
72-18	11889-11892	and	_
72-19	11893-11905	interactions	_
72-20	11906-11913	between	_
72-21	11914-11919	these	_
72-22	11920-11927	factors	_
72-23	11928-11935	related	_
72-24	11936-11938	to	_
72-25	11939-11942	our	_
72-26	11943-11944	4	_
72-27	11945-11954	dependent	_
72-28	11955-11964	variables	_
72-29	11965-11967	of	_
72-30	11968-11976	interest	_
72-31	11977-11978	(	_
72-32	11979-11987	negative	_
72-33	11988-11992	mood	_
72-34	11993-11994	,	_
72-35	11995-12003	positive	_
72-36	12004-12008	mood	_
72-37	12009-12010	,	_
72-38	12011-12019	negative	_
72-39	12020-12028	symptoms	_
72-40	12029-12030	,	_
72-41	12031-12034	and	_
72-42	12035-12043	positive	_
72-43	12044-12052	symptoms	_
72-44	12053-12054	)	_
72-45	12055-12056	.	_

73-1	12057-12059	By	_
73-2	12060-12061	“	_
73-3	12062-12070	same-day	_
73-4	12071-12079	conflict	_
73-5	12080-12088	distress	_
73-6	12089-12090	”	_
73-7	12091-12093	we	_
73-8	12094-12098	mean	_
73-9	12099-12102	the	_
73-10	12103-12110	maximum	_
73-11	12111-12119	distress	_
73-12	12120-12126	rating	_
73-13	12127-12130	for	_
73-14	12131-12140	conflicts	_
73-15	12141-12152	experienced	_
73-16	12153-12155	on	_
73-17	12156-12159	the	_
73-18	12160-12164	same	_
73-19	12165-12168	day	_
73-20	12169-12171	as	_
73-21	12172-12181	dependent	_
73-22	12182-12190	variable	_
73-23	12191-12198	ratings	_
73-24	12199-12200	.	_

74-1	12201-12203	We	_
74-2	12204-12216	hypothesized	_
74-3	12217-12226	three-way	_
74-4	12227-12239	interactions	_
74-5	12240-12243	for	_
74-6	12244-12249	these	_
74-7	12250-12256	models	_
74-8	12257-12261	such	_
74-9	12262-12266	that	_
74-10	12267-12270	the	_
74-11	12271-12282	combination	_
74-12	12283-12285	of	_
74-13	12286-12297	distressing	_
74-14	12298-12304	social	_
74-15	12305-12314	conflicts	_
74-16	12315-12318	and	_
74-17	12319-12323	weak	_
74-18	12324-12329	DLPFC	_
74-19	12330-12338	activity	_
74-20	12339-12344	would	_
74-21	12345-12347	be	_
74-22	12348-12358	associated	_
74-23	12359-12363	with	_
74-24	12364-12375	exacerbated	_
74-25	12376-12380	mood	_
74-26	12381-12384	and	_
74-27	12385-12392	symptom	_
74-28	12393-12404	disturbance	_
74-29	12405-12417	specifically	_
74-30	12418-12420	in	_
74-31	12421-12424	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
74-32	12425-12436	individuals	_
74-33	12437-12438	.	_

75-1	12439-12440	A	_
75-2	12441-12447	second	_
75-3	12448-12451	set	_
75-4	12452-12454	of	_
75-5	12455-12463	analyses	_
75-6	12464-12472	examined	_
75-7	12473-12480	whether	_
75-8	12481-12486	DLPFC	_
75-9	12487-12495	activity	_
75-10	12496-12497	,	_
75-11	12498-12501	FHR	_
75-12	12502-12508	status	_
75-13	12509-12510	,	_
75-14	12511-12514	and	_
75-15	12515-12521	social	_
75-16	12522-12530	conflict	_
75-17	12531-12539	impacted	_
75-18	12540-12549	dependent	_
75-19	12550-12559	variables	_
75-20	12560-12562	on	_
75-21	12563-12566	the	_
75-22	12567-12570	day	_
75-23	12571-12580	following	_
75-24	12581-12590	conflicts	_
75-25	12591-12592	.	_

76-1	12593-12595	We	_
76-2	12596-12601	refer	_
76-3	12602-12604	to	_
76-4	12605-12610	these	_
76-5	12611-12619	analyses	_
76-6	12620-12622	as	_
76-7	12623-12624	“	_
76-8	12625-12638	following-day	_
76-9	12639-12648	analyses.	_
76-10	12649-12650	”	_
76-11	12651-12656	These	_
76-12	12657-12665	analyses	_
76-13	12666-12674	included	_
76-14	12675-12680	DLPFC	_
76-15	12681-12689	activity	_
76-16	12690-12691	,	_
76-17	12692-12695	FHR	_
76-18	12696-12702	status	_
76-19	12703-12704	,	_
76-20	12705-12717	previous-day	_
76-21	12718-12726	conflict	_
76-22	12727-12735	distress	_
76-23	12736-12737	,	_
76-24	12738-12741	and	_
76-25	12742-12747	their	_
76-26	12748-12760	interactions	_
76-27	12761-12763	as	_
76-28	12764-12769	fixed	_
76-29	12770-12777	effects	_
76-30	12778-12779	.	_

77-1	12780-12782	By	_
77-2	12783-12784	“	_
77-3	12785-12797	previous-day	_
77-4	12798-12806	conflict	_
77-5	12807-12815	distress	_
77-6	12816-12817	,	_
77-7	12818-12819	”	_
77-8	12820-12822	we	_
77-9	12823-12827	mean	_
77-10	12828-12831	the	_
77-11	12832-12839	maximum	_
77-12	12840-12848	conflict	_
77-13	12849-12857	distress	_
77-14	12858-12869	experienced	_
77-15	12870-12872	on	_
77-16	12873-12876	the	_
77-17	12877-12880	day	_
77-18	12881-12887	before	_
77-19	12888-12897	dependent	_
77-20	12898-12906	variable	_
77-21	12907-12914	ratings	_
77-22	12915-12916	.	_

78-1	12917-12922	These	_
78-2	12923-12931	analyses	_
78-3	12932-12935	let	_
78-4	12936-12938	us	_
78-5	12939-12940	(	_
78-6	12941-12942	i	_
78-7	12943-12944	)	_
78-8	12945-12952	examine	_
78-9	12953-12960	whether	_
78-10	12961-12967	social	_
78-11	12968-12976	conflict	_
78-12	12977-12985	impacted	_
78-13	12986-12998	participants	_
78-14	12999-13003	even	_
78-15	13004-13007	the	_
78-16	13008-13011	day	_
78-17	13012-13017	after	_
78-18	13018-13019	a	_
78-19	13020-13028	conflict	_
78-20	13029-13032	and	_
78-21	13033-13034	(	_
78-22	13035-13037	ii	_
78-23	13038-13039	)	_
78-24	13040-13049	establish	_
78-25	13050-13057	whether	_
78-26	13058-13064	social	_
78-27	13065-13073	conflict	_
78-28	13074-13084	temporally	_
78-29	13085-13093	preceded	_
78-30	13094-13101	changes	_
78-31	13102-13104	in	_
78-32	13105-13114	dependent	_
78-33	13115-13124	variables	_
78-34	13125-13126	.	_

79-1	13127-13129	We	_
79-2	13130-13135	again	_
79-3	13136-13148	hypothesized	_
79-4	13149-13158	three-way	_
79-5	13159-13171	interactions	_
79-6	13172-13176	such	_
79-7	13177-13181	that	_
79-8	13182-13186	weak	_
79-9	13187-13192	DLPFC	_
79-10	13193-13201	activity	_
79-11	13202-13205	and	_
79-12	13206-13209	FHR	_
79-13	13210-13216	status	_
79-14	13217-13222	would	_
79-15	13223-13225	be	_
79-16	13226-13238	specifically	_
79-17	13239-13249	associated	_
79-18	13250-13254	with	_
79-19	13255-13266	exacerbated	_
79-20	13267-13271	mood	_
79-21	13272-13275	and	_
79-22	13276-13283	symptom	_
79-23	13284-13295	disturbance	_
79-24	13296-13298	on	_
79-25	13299-13303	days	_
79-26	13304-13313	following	_
79-27	13314-13325	distressing	_
79-28	13326-13332	social	_
79-29	13333-13342	conflicts	_
79-30	13343-13344	.	_

80-1	13345-13348	For	_
80-2	13349-13353	both	_
80-3	13354-13362	same-day	_
80-4	13363-13366	and	_
80-5	13367-13380	following-day	_
80-6	13381-13389	analyses	_
80-7	13390-13391	,	_
80-8	13392-13396	each	_
80-9	13397-13406	dependent	_
80-10	13407-13415	variable	_
80-11	13416-13417	(	_
80-12	13418-13422	i.e.	_
80-13	13423-13424	,	_
80-14	13425-13433	negative	_
80-15	13434-13438	mood	_
80-16	13439-13440	,	_
80-17	13441-13449	positive	_
80-18	13450-13454	mood	_
80-19	13455-13456	,	_
80-20	13457-13465	negative	_
80-21	13466-13474	symptoms	_
80-22	13475-13476	,	_
80-23	13477-13480	and	_
80-24	13481-13489	positive	_
80-25	13490-13498	symptoms	_
80-26	13499-13500	)	_
80-27	13501-13504	was	_
80-28	13505-13512	modeled	_
80-29	13513-13515	at	_
80-30	13516-13519	the	_
80-31	13520-13525	daily	_
80-32	13526-13531	level	_
80-33	13532-13534	in	_
80-34	13535-13536	a	_
80-35	13537-13545	separate	_
80-36	13546-13559	mixed-effects	_
80-37	13560-13565	model	_
80-38	13566-13567	.	_

81-1	13568-13580	Fixed-effect	_
81-2	13581-13591	predictors	_
81-3	13592-13594	of	_
81-4	13595-13603	interest	_
81-5	13604-13612	included	_
81-6	13613-13618	group	_
81-7	13619-13620	(	_
81-8	13621-13624	FHR	_
81-9	13625-13628	vs.	_
81-10	13629-13636	non-FHR	_
81-11	13637-13638	)	_
81-12	13639-13640	,	_
81-13	13641-13649	conflict	_
81-14	13650-13658	distress	_
81-15	13659-13660	(	_
81-16	13661-13664	0–5	_
81-17	13665-13672	maximum	_
81-18	13673-13681	distress	_
81-19	13682-13685	due	_
81-20	13686-13688	to	_
81-21	13689-13697	conflict	_
81-22	13698-13704	either	_
81-23	13705-13709	that	_
81-24	13710-13713	day	_
81-25	13714-13716	or	_
81-26	13717-13720	the	_
81-27	13721-13729	previous	_
81-28	13730-13733	day	_
81-29	13734-13735	)	_
81-30	13736-13737	,	_
81-31	13738-13744	neural	_
81-32	13745-13753	response	_
81-33	13754-13756	to	_
81-34	13757-13766	criticism	_
81-35	13767-13768	(	_
81-36	13769-13778	bilateral	_
81-37	13779-13784	DLPFC	_
81-38	13785-13789	beta	_
81-39	13790-13791	)	_
81-40	13792-13793	,	_
81-41	13794-13797	and	_
81-42	13798-13801	the	_
81-43	13802-13814	interactions	_
81-44	13815-13822	between	_
81-45	13823-13828	these	_
81-46	13829-13834	three	_
81-47	13835-13845	predictors	_
81-48	13846-13847	.	_

82-1	13848-13852	Note	_
82-2	13853-13857	that	_
82-3	13858-13862	each	_
82-4	13863-13874	participant	_
82-5	13875-13877	's	_
82-6	13878-13883	daily	_
82-7	13884-13892	conflict	_
82-8	13893-13901	distress	_
82-9	13902-13905	and	_
82-10	13906-13913	overall	_
82-11	13914-13920	neural	_
82-12	13921-13929	response	_
82-13	13930-13932	to	_
82-14	13933-13942	criticism	_
82-15	13943-13947	were	_
82-16	13948-13953	input	_
82-17	13954-13956	as	_
82-18	13957-13967	continuous	_
82-19	13968-13976	measures	_
82-20	13977-13978	:	_
82-21	13979-13984	These	_
82-22	13985-13994	variables	_
82-23	13995-13999	were	_
82-24	14000-14003	not	_
82-25	14004-14009	split	_
82-26	14010-14014	into	_
82-27	14015-14025	categories	_
82-28	14026-14030	even	_
82-29	14031-14037	though	_
82-30	14038-14047	predicted	_
82-31	14048-14054	values	_
82-32	14055-14058	for	_
82-33	14059-14066	extreme	_
82-34	14067-14073	groups	_
82-35	14074-14077	are	_
82-36	14078-14087	presented	_
82-37	14088-14090	in	_
82-38	14091-14098	figures	_
82-39	14099-14101	to	_
82-40	14102-14112	illustrate	_
82-41	14113-14116	the	_
82-42	14117-14129	interactions	_
82-43	14130-14131	.	_

83-1	14132-14138	Models	_
83-2	14139-14149	controlled	_
83-3	14150-14153	for	_
83-4	14154-14159	diary	_
83-5	14160-14163	day	_
83-6	14164-14167	and	_
83-7	14168-14171	the	_
83-8	14172-14180	previous	_
83-9	14181-14184	day	_
83-10	14185-14187	's	_
83-11	14188-14193	level	_
83-12	14194-14196	of	_
83-13	14197-14201	each	_
83-14	14202-14211	dependent	_
83-15	14212-14220	variable	_
83-16	14221-14222	.	_

84-1	14223-14234	Controlling	_
84-2	14235-14238	for	_
84-3	14239-14242	the	_
84-4	14243-14255	previous-day	_
84-5	14256-14262	rating	_
84-6	14263-14265	of	_
84-7	14266-14275	dependent	_
84-8	14276-14285	variables	_
84-9	14286-14297	effectively	_
84-10	14298-14303	means	_
84-11	14304-14306	we	_
84-12	14307-14314	modeled	_
84-13	14315-14318	the	_
84-14	14319-14325	change	_
84-15	14326-14328	in	_
84-16	14329-14332	the	_
84-17	14333-14342	dependent	_
84-18	14343-14351	variable	_
84-19	14352-14356	from	_
84-20	14357-14360	the	_
84-21	14361-14369	previous	_
84-22	14370-14373	day	_
84-23	14374-14375	.	_

85-1	14376-14378	We	_
85-2	14379-14380	“	_
85-3	14381-14387	nested	_
85-4	14388-14389	”	_
85-5	14390-14394	days	_
85-6	14395-14401	within	_
85-7	14402-14414	participants	_
85-8	14415-14417	by	_
85-9	14418-14426	modeling	_
85-10	14427-14439	participants	_
85-11	14440-14442	as	_
85-12	14443-14444	a	_
85-13	14445-14451	random	_
85-14	14452-14458	effect	_
85-15	14459-14460	.	_

86-1	14461-14466	Diary	_
86-2	14467-14470	day	_
86-3	14471-14474	was	_
86-4	14475-14482	allowed	_
86-5	14483-14485	to	_
86-6	14486-14490	have	_
86-7	14491-14492	a	_
86-8	14493-14499	random	_
86-9	14500-14505	slope	_
86-10	14506-14512	across	_
86-11	14513-14525	participants	_
86-12	14526-14527	.	_

87-1	14528-14531	All	_
87-2	14532-14542	continuous	_
87-3	14543-14553	predictors	_
87-4	14554-14558	were	_
87-5	14559-14567	centered	_
87-6	14568-14569	.	_

88-1	14570-14572	We	_
88-2	14573-14581	unpacked	_
88-3	14582-14593	significant	_
88-4	14594-14606	interactions	_
88-5	14607-14614	between	_
88-6	14615-14623	conflict	_
88-7	14624-14632	distress	_
88-8	14633-14636	and	_
88-9	14637-14642	DLPFC	_
88-10	14643-14651	activity	_
88-11	14652-14657	using	_
88-12	14658-14664	simple	_
88-13	14665-14671	slopes	_
88-14	14672-14680	analyses	_
88-15	14681-14682	.	_

89-1	14683-14688	These	_
89-2	14689-14697	analyses	_
89-3	14698-14705	dissect	_
89-4	14706-14718	interactions	_
89-5	14719-14722	and	_
89-6	14723-14730	uncover	_
89-7	14731-14736	which	_
89-8	14737-14749	combinations	_
89-9	14750-14752	of	_
89-10	14753-14758	group	_
89-11	14759-14765	status	_
89-12	14766-14767	,	_
89-13	14768-14773	DLPFC	_
89-14	14774-14782	activity	_
89-15	14783-14784	,	_
89-16	14785-14788	and	_
89-17	14789-14797	conflict	_
89-18	14798-14806	distress	_
89-19	14807-14811	were	_
89-20	14812-14822	associated	_
89-21	14823-14827	with	_
89-22	14828-14836	outcomes	_
89-23	14837-14838	.	_

90-1	14839-14844	These	_
90-2	14845-14853	analyses	_
90-3	14854-14866	specifically	_
90-4	14867-14873	tested	_
90-5	14874-14881	whether	_
90-6	14882-14887	DLPFC	_
90-7	14888-14896	activity	_
90-8	14897-14900	was	_
90-9	14901-14911	associated	_
90-10	14912-14916	with	_
90-11	14917-14921	mood	_
90-12	14922-14924	or	_
90-13	14925-14932	symptom	_
90-14	14933-14939	levels	_
90-15	14940-14946	within	_
90-16	14947-14951	both	_
90-17	14952-14955	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
90-18	14956-14959	and	_
90-19	14960-14967	non-FHR	_
90-20	14968-14974	groups	_
90-21	14975-14977	on	_
90-22	14978-14982	days	_
90-23	14983-14987	with	_
90-24	14988-14992	high	_
90-25	14993-14995	or	_
90-26	14996-14999	low	_
90-27	15000-15008	conflict	_
90-28	15009-15017	distress	_
90-29	15018-15019	.	_

91-1	15020-15024	Such	_
91-2	15025-15034	piecewise	_
91-3	15035-15043	analyses	_
91-4	15044-15051	clarify	_
91-5	15052-15057	which	_
91-6	15058-15063	group	_
91-7	15064-15067	and	_
91-8	15068-15073	level	_
91-9	15074-15076	of	_
91-10	15077-15085	conflict	_
91-11	15086-15094	distress	_
91-12	15095-15100	drove	_
91-13	15101-15113	interactions	_
91-14	15114-15115	,	_
91-15	15116-15123	thereby	_
91-16	15124-15131	testing	_
91-17	15132-15139	whether	_
91-18	15140-15152	interactions	_
91-19	15153-15157	were	_
91-20	15158-15161	due	_
91-21	15162-15164	to	_
91-22	15165-15168	the	_
91-23	15169-15181	hypothesized	_
91-24	15182-15189	pattern	_
91-25	15190-15192	of	_
91-26	15193-15200	results	_
91-27	15201-15202	(	_
91-28	15203-15207	i.e.	_
91-29	15208-15209	,	_
91-30	15210-15214	weak	_
91-31	15215-15220	DLPFC	_
91-32	15221-15229	activity	_
91-33	15230-15232	is	_
91-34	15233-15243	associated	_
91-35	15244-15248	with	_
91-36	15249-15257	elevated	_
91-37	15258-15262	mood	_
91-38	15263-15266	and	_
91-39	15267-15274	symptom	_
91-40	15275-15285	expression	_
91-41	15286-15288	in	_
91-42	15289-15292	FHR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
91-43	15293-15305	participants	_
91-44	15306-15315	following	_
91-45	15316-15327	distressing	_
91-46	15328-15337	conflicts	_
91-47	15338-15339	)	_
91-48	15340-15341	.	_

92-1	15342-15345	For	_
92-2	15346-15350	each	_
92-3	15351-15356	group	_
92-4	15357-15358	,	_
92-5	15359-15365	simple	_
92-6	15366-15371	slope	_
92-7	15372-15380	analyses	_
92-8	15381-15389	assessed	_
92-9	15390-15397	whether	_
92-10	15398-15402	high	_
92-11	15403-15405	or	_
92-12	15406-15409	low	_
92-13	15410-15415	DLPFC	_
92-14	15416-15424	activity	_
92-15	15425-15426	(	_
92-16	15427-15428	1	_
92-17	15429-15431	SD	_
92-18	15432-15436	from	_
92-19	15437-15441	each	_
92-20	15442-15447	group	_
92-21	15448-15450	's	_
92-22	15451-15455	mean	_
92-23	15456-15457	)	_
92-24	15458-15461	was	_
92-25	15462-15475	significantly	_
92-26	15476-15486	associated	_
92-27	15487-15491	with	_
92-28	15492-15496	each	_
92-29	15497-15506	dependent	_
92-30	15507-15515	variable	_
92-31	15516-15518	on	_
92-32	15519-15523	days	_
92-33	15524-15528	with	_
92-34	15529-15531	no	_
92-35	15532-15533	(	_
92-36	15534-15535	0	_
92-37	15536-15537	=	_
92-38	15538-15546	conflict	_
92-39	15547-15553	absent	_
92-40	15554-15555	)	_
92-41	15556-15558	or	_
92-42	15559-15566	maximal	_
92-43	15567-15568	(	_
92-44	15569-15570	5	_
92-45	15571-15572	=	_
92-46	15573-15582	extremely	_
92-47	15583-15594	distressing	_
92-48	15595-15596	)	_
92-49	15597-15605	conflict	_
92-50	15606-15614	distress	_
92-51	15615-15616	.	_

93-1	15617-15619	We	_
93-2	15620-15626	tested	_
93-3	15627-15630	the	_
93-4	15631-15643	significance	_
93-5	15644-15646	of	_
93-6	15647-15653	simple	_
93-7	15654-15660	slopes	_
93-8	15661-15663	in	_
93-9	15664-15665	R	_
93-10	15666-15671	using	_
93-11	15672-15675	the	_
93-12	15676-15684	pbkrtest	_
93-13	15685-15692	package	_
93-14	15693-15694	,	_
93-15	15695-15700	which	_
93-16	15701-15709	conducts	_
93-17	15710-15712	an	_
93-18	15713-15719	F-test	_
93-19	15720-15725	using	_
93-20	15726-15752	Kenward-Roger-approximated	_
93-21	15753-15760	degrees	_
93-22	15761-15763	of	_
93-23	15764-15771	freedom	_
93-24	15772-15773	.	_

94-1	15774-15784	Correction	_
94-2	15785-15788	for	_
94-3	15789-15797	multiple	_
94-4	15798-15809	comparisons	_
94-5	15810-15818	Although	_
94-6	15819-15831	mixed-effect	_
94-7	15832-15837	model	_
94-8	15838-15846	analyses	_
94-9	15847-15851	were	_
94-10	15852-15859	planned	_
94-11	15860-15861	a	_
94-12	15862-15868	priori	_
94-13	15869-15870	,	_
94-14	15871-15876	these	_
94-15	15877-15885	analyses	_
94-16	15886-15894	involved	_
94-17	15895-15896	a	_
94-18	15897-15902	large	_
94-19	15903-15909	number	_
94-20	15910-15912	of	_
94-21	15913-15924	comparisons	_
94-22	15925-15926	.	_

95-1	15927-15932	Hence	_
95-2	15933-15934	,	_
95-3	15935-15937	we	_
95-4	15938-15949	implemented	_
95-5	15950-15953	the	_
95-6	15954-15960	method	_
95-7	15961-15963	to	_
95-8	15964-15974	facilitate	_
95-9	15975-15989	interpretation	_
95-10	15990-15992	of	_
95-11	15993-15998	which	_
95-12	15999-16006	results	_
95-13	16007-16015	survived	_
95-14	16016-16026	correction	_
95-15	16027-16030	for	_
95-16	16031-16039	multiple	_
95-17	16040-16051	comparisons	_
95-18	16052-16053	.	_

96-1	16054-16058	Each	_
96-2	16059-16068	predictor	_
96-3	16069-16075	across	_
96-4	16076-16079	all	_
96-5	16080-16081	8	_
96-6	16082-16090	analyses	_
96-7	16091-16094	was	_
96-8	16095-16105	considered	_
96-9	16106-16107	a	_
96-10	16108-16116	separate	_
96-11	16117-16121	test	_
96-12	16122-16123	.	_

97-1	16124-16126	We	_
97-2	16127-16133	report	_
97-3	16134-16141	results	_
97-4	16142-16146	that	_
97-5	16147-16154	persist	_
97-6	16155-16164	following	_
97-7	16165-16169	this	_
97-8	16170-16180	correction	_
97-9	16181-16183	in	_
97-10	16184-16189	Table	_
97-11	16190-16191	3	_
97-12	16192-16193	.	_

98-1	16194-16203	Follow-up	_
98-2	16204-16211	control	_
98-3	16212-16220	analyses	_
98-4	16221-16230	including	_
98-5	16231-16241	covariates	_
98-6	16242-16244	We	_
98-7	16245-16254	conducted	_
98-8	16255-16256	a	_
98-9	16257-16263	series	_
98-10	16264-16266	of	_
98-11	16267-16276	follow-up	_
98-12	16277-16284	control	_
98-13	16285-16293	analyses	_
98-14	16294-16296	to	_
98-15	16297-16303	verify	_
98-16	16304-16308	that	_
98-17	16309-16312	age	_
98-18	16313-16314	,	_
98-19	16315-16321	gender	_
98-20	16322-16323	,	_
98-21	16324-16334	depressive	_
98-22	16335-16343	symptoms	_
98-23	16344-16345	(	_
98-24	16346-16354	assessed	_
98-25	16355-16357	by	_
98-26	16358-16361	the	_
98-27	16362-16368	BDI-II	_
98-28	16369-16370	)	_
98-29	16371-16372	,	_
98-30	16373-16376	and	_
98-31	16377-16383	having	_
98-32	16384-16385	a	_
98-33	16386-16395	diagnosis	_
98-34	16396-16398	of	_
98-35	16399-16408	substance	_
98-36	16409-16414	abuse	_
98-37	16415-16418	did	_
98-38	16419-16422	not	_
98-39	16423-16431	confound	_
98-40	16432-16435	our	_
98-41	16436-16443	results	_
98-42	16444-16445	.	_

99-1	16446-16448	To	_
99-2	16449-16453	test	_
99-3	16454-16461	whether	_
99-4	16462-16469	primary	_
99-5	16470-16477	results	_
99-6	16478-16485	existed	_
99-7	16486-16490	even	_
99-8	16491-16496	after	_
99-9	16497-16508	controlling	_
99-10	16509-16512	for	_
99-11	16513-16518	these	_
99-12	16519-16528	variables	_
99-13	16529-16530	,	_
99-14	16531-16533	we	_
99-15	16534-16539	added	_
99-16	16540-16545	these	_
99-17	16546-16555	variables	_
99-18	16556-16558	as	_
99-19	16559-16571	simultaneous	_
99-20	16572-16582	covariates	_
99-21	16583-16585	in	_
99-22	16586-16587	a	_
99-23	16588-16591	set	_
99-24	16592-16594	of	_
99-25	16595-16604	secondary	_
99-26	16605-16613	analyses	_
99-27	16614-16615	.	_

100-1	16616-16618	We	_
100-2	16619-16625	report	_
100-3	16626-16633	results	_
100-4	16634-16636	of	_
100-5	16637-16642	these	_
100-6	16643-16650	control	_
100-7	16651-16659	analyses	_
100-8	16660-16662	in	_
100-9	16663-16666	the	_
100-10	16667-16674	results	_
100-11	16675-16683	sections	_
100-12	16684-16689	below	_
100-13	16690-16691	.	_

101-1	16692-16696	Note	_
101-2	16697-16701	that	_
101-3	16702-16707	these	_
101-4	16708-16716	analyses	_
101-5	16717-16725	included	_
101-6	16726-16730	only	_
101-7	16731-16732	a	_
101-8	16733-16739	subset	_
101-9	16740-16742	of	_
101-10	16743-16755	participants	_
101-11	16756-16763	because	_
101-12	16764-16768	data	_
101-13	16769-16778	regarding	_
101-14	16779-16785	Axis-I	_
101-15	16786-16795	diagnoses	_
101-16	16796-16800	were	_
101-17	16801-16804	not	_
101-18	16805-16814	available	_
101-19	16815-16818	for	_
101-20	16819-16820	5	_
101-21	16821-16833	participants	_
101-22	16834-16837	and	_
101-23	16838-16844	BDI-II	_
101-24	16845-16851	scores	_
101-25	16852-16856	were	_
101-26	16857-16860	not	_
101-27	16861-16870	available	_
101-28	16871-16874	for	_
101-29	16875-16876	2	_
101-30	16877-16887	additional	_
101-31	16888-16900	participants	_
101-32	16901-16902	.	_

102-1	16903-16916	Demonstrating	_
102-2	16917-16921	that	_
102-3	16922-16929	results	_
102-4	16930-16936	remain	_
102-5	16937-16942	after	_
102-6	16943-16954	controlling	_
102-7	16955-16958	for	_
102-8	16959-16964	these	_
102-9	16965-16974	variables	_
102-10	16975-16984	increases	_
102-11	16985-16995	confidence	_
102-12	16996-16998	in	_
102-13	16999-17002	the	_
102-14	17003-17008	study	_
102-15	17009-17011	's	_
102-16	17012-17020	findings	_
102-17	17021-17024	and	_
102-18	17025-17033	suggests	_
102-19	17034-17038	they	_
102-20	17039-17042	are	_
102-21	17043-17046	not	_
102-22	17047-17056	explained	_
102-23	17057-17059	by	_
102-24	17060-17063	any	_
102-25	17064-17066	of	_
102-26	17067-17072	these	_
102-27	17073-17084	potentially	_
102-28	17085-17096	confounding	_
102-29	17097-17106	variables	_
102-30	17107-17108	.	_

